Congress Denies FDA Power to Regulate Tobacco Products

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 3
Volume 14
Issue 3

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.

WASHINGTON-Hope thatthe FDA would finally gain authorityto regulate tobacco products moreaggressively was dashed when a House-Senate conference committee droppedthe provision, which the Senate hadpassed as part of the 2004 Foreign SalesCorporation (FSC) tax cut bill. Thelegislation, which President Bushsigned into law on Oct. 24, did containa $10 billion buy-out package for tobaccofarmers, that will end a federaltobacco crop quota system institutedduring the Depression.The Senate passed the tobacco-regulationprovision in July by a 78 to 15vote, the first time either house hadvoted FDA regulatory power over thetobacco industry. The Senate's actionsent the expectations of public healthand anti-tobacco organizations soaring.A joint statement by four groupscalled the Senate vote "a giant steptoward a national tobacco policy thatcan significantly reduce the numberof children who become addicted totobacco products and the number ofpeople who die each year from tobacco-caused disease."However, the House version of theFSC bill did not include the tobaccoregulation powers, and in the conference committee to resolve differencesbetween the two measures, House negotiatorsled by Rep. Bill Thomas(R-Calif) refused to accept the Senateprovision in the bill.The tobacco industry lobbiedstrenuously to defeat the attempt toregulate its products. Coincidentally,the Campaign for Tobacco-Free Kidsreleased its quarterly report on theindustry's contributions to federalcandidates 9 days after the conferencecommittee reported the final versionof the FSC bill. It showed totaldonations during the 2003-2004 electioncycles of $2.8 million.

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Related Content